An Open Label, Fixed-Sequence, Glucose Clamp Study to Compare Molar Potency of HM12460A and Insulin Glargine in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2018
Price : $35 *
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 06 Mar 2018 Last checked against ClinicalTrials.gov record.
- 26 Feb 2018 Status changed from recruiting to completed.
- 08 Nov 2017 New trial record